Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 10 |
| List of Tables | 9 | 3 |
| List of Figures | 12 | 3 |
| Novel Therapies in Oncology - Introduction | 15 | 1 |
| Novel Therapies in Oncology - Key Innovations and Technologies | 16 | 11 |
| Introduction | 16 | 1 |
| Increase in Cancer | 17 | 1 |
| Risk Factors for Cancer | 17 | 1 |
| Oncology Treatment Pathways | 17 | 1 |
| Chemotherapeutics | 17 | 1 |
| Targeted Therapies | 18 | 1 |
| Leading Marketed Drugs in Oncology | 18 | 1 |
| Rituxan/ MabThera | 18 | 1 |
| Introduction | 18 | 1 |
| Revenues | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| Herceptin | 19 | 1 |
| Introduction | 19 | 1 |
| Revenues | 19 | 1 |
| Mechanism of Action | 20 | 1 |
| Gleevec/Glivec | 20 | 1 |
| Introduction | 20 | 1 |
| Revenues | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| Avastin | 21 | 1 |
| Introduction | 21 | 1 |
| Revenues | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| Eloxatin | 21 | 1 |
| Introduction | 21 | 1 |
| Revenues | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| Erbitux | 22 | 1 |
| Introduction | 22 | 1 |
| Revenues | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| Xeloda | 22 | 1 |
| Introduction | 22 | 1 |
| Revenues | 22 | 1 |
| Mechanism of Action | 23 | 1 |
| Femara | 23 | 1 |
| Introduction | 23 | 1 |
| Revenues | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| Temodar | 23 | 1 |
| Introduction | 23 | 1 |
| Revenues | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| Tarceva | 24 | 1 |
| Introduction | 24 | 1 |
| Revenues | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| Taxotere | 25 | 1 |
| Introduction | 25 | 1 |
| Revenues | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| Revlimid | 25 | 1 |
| Introduction | 25 | 1 |
| Revenues | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| Alimta | 26 | 1 |
| Introduction | 26 | 1 |
| Revenues | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| Novel Therapies in Oncology - Leading Novel Drug Classes for the Future | 27 | 4 |
| Protein Kinase Inhibitors | 27 | 1 |
| Vaccines | 28 | 1 |
| Tumor Cell Vaccines | 29 | 1 |
| Autologous Vaccines | 29 | 1 |
| Allogeneic Vaccines | 29 | 1 |
| Antigen Vaccines | 29 | 1 |
| Dendritic Cell Vaccines | 30 | 1 |
| Anti-Idiotype vaccines | 30 | 1 |
| Novel Therapies in Oncology - Opportunity and Unmet Need Analysis | 31 | 12 |
| Breast Cancer | 31 | 2 |
| Colorectal Cancer | 33 | 1 |
| NHL | 34 | 2 |
| NSCLC | 36 | 2 |
| Prostate Cancer | 38 | 1 |
| Ovarian Cancer | 39 | 1 |
| Cervical Cancer | 40 | 1 |
| Head and Neck Cancer | 41 | 2 |
| Novel Therapies in Oncology - Product Pipeline Analysis | 43 | 97 |
| Introduction | 43 | 4 |
| Breast Cancer | 47 | 1 |
| Breast Cancer Pipeline - Introduction | 47 | 1 |
| Breast Cancer Pipeline - Analysis by Therapeutic Class | 48 | 1 |
| Pre-Clinical | 48 | 1 |
| Discovery | 49 | 1 |
| Phase I | 50 | 1 |
| Phase II | 51 | 1 |
| Phase III | 52 | 1 |
| NDA Filed | 52 | 1 |
| Breast Cancer Pipeline - Pre-Clinical | 53 | 1 |
| Breast Cancer Pipeline - Discovery | 54 | 1 |
| Breast Cancer Pipeline - Phase I | 55 | 2 |
| Breast Cancer Pipeline - Phase II | 57 | 4 |
| Breast Cancer Pipeline - Phase III | 61 | 1 |
| Breast Cancer Pipeline - NDA Filed | 61 | 1 |
| Colorectal Cancer | 62 | 1 |
| Colorectal Cancer Pipeline - Introduction | 62 | 1 |
| Colorectal Cancer Pipeline - Analysis by Therapeutic Class | 63 | 1 |
| Pre-Clinical | 63 | 1 |
| Discovery | 64 | 1 |
| Phase I | 65 | 1 |
| Phase II | 66 | 1 |
| Phase III | 67 | 1 |
| Colorectal Cancer Pipeline - Pre-Clinical | 68 | 1 |
| Colorectal Cancer Pipeline - Discovery | 68 | 1 |
| Colorectal Cancer Pipeline - Phase I | 69 | 2 |
| Colorectal Cancer Pipeline - Phase II | 71 | 3 |
| Colorectal Cancer Pipeline - Phase III | 74 | 1 |
| NHL | 75 | 1 |
| NHL Pipeline - Introduction | 75 | 1 |
| NHL Pipeline - Analysis by Therapeutic Class | 76 | 1 |
| Pre-Clinical | 76 | 1 |
| Discovery | 77 | 1 |
| Phase I | 78 | 1 |
| Phase II | 79 | 1 |
| Phase III | 80 | 1 |
| NDA Filed | 80 | 1 |
| NHL Pipeline - Pre-Clinical | 81 | 1 |
| NHL Pipeline - Discovery | 81 | 1 |
| NHL Pipeline - Phase I | 82 | 2 |
| NHL Pipeline - Phase II | 84 | 1 |
| NHL Pipeline - Phase III | 85 | 1 |
| NHL Pipeline - NDA Filed | 85 | 1 |
| NSCLC | 86 | 1 |
| NSCLC Pipeline - Introduction | 86 | 1 |
| NSCLC Pipeline - Analysis by Therapeutic Class | 87 | 1 |
| Pre-Clinical | 87 | 1 |
| Discovery | 88 | 1 |
| Phase I | 89 | 1 |
| Phase II | 90 | 1 |
| Phase III | 91 | 1 |
| NDA Filed | 92 | 1 |
| NSCLC Pipeline - Pre-Clinical | 93 | 1 |
| NSCLC Pipeline - Discovery | 94 | 1 |
| NSCLC Pipeline - Phase I | 94 | 1 |
| NSCLC Pipeline - Phase II | 95 | 2 |
| NSCLC Pipeline - Phase III | 97 | 1 |
| NSCLC Pipeline - NDA Filed | 98 | 1 |
| Prostate Cancer | 99 | 1 |
| Prostate Cancer Pipeline - Introduction | 99 | 1 |
| Prostate Cancer Pipeline - Analysis by Therapeutic Class | 100 | 1 |
| Pre-Clinical | 100 | 1 |
| Discovery | 101 | 1 |
| Phase I | 102 | 1 |
| Phase II | 103 | 1 |
| Phase III | 104 | 1 |
| NDA Filed | 105 | 1 |
| Prostate Cancer Pipeline - Pre-Clinical | 106 | 1 |
| Prostate Cancer Pipeline - Discovery | 107 | 1 |
| Prostate Cancer Pipeline - Phase I | 108 | 1 |
| Prostate Cancer Pipeline - Phase II | 109 | 2 |
| Prostate Cancer Pipeline - Phase III | 111 | 1 |
| Prostate Cancer Pipeline - NDA Filed | 112 | 1 |
| Ovarian Cancer | 112 | 1 |
| Ovarian Cancer Pipeline - Introduction | 112 | 1 |
| Ovarian Cancer Pipeline - Analysis by Therapeutic Class | 113 | 1 |
| Pre-Clinical | 113 | 1 |
| Discovery | 113 | 1 |
| Phase I | 114 | 1 |
| Phase II | 115 | 1 |
| Phase III | 116 | 1 |
| Ovarian Cancer Pipeline - Pre-Clinical | 117 | 1 |
| Ovarian Cancer Pipeline - Discovery | 118 | 1 |
| Ovarian Cancer Pipeline - Phase I | 119 | 1 |
| Ovarian Cancer Pipeline - Phase II | 120 | 2 |
| Ovarian Cancer Pipeline - Phase III | 122 | 1 |
| Ovarian Cancer Pipeline - NDA Filed | 122 | 1 |
| Cervical Cancer | 123 | 1 |
| Cervical Cancer Pipeline - Introduction | 123 | 1 |
| Cervical Cancer Pipeline - Analysis by Therapeutic Class | 124 | 1 |
| Pre-Clinical | 124 | 1 |
| Phase I | 125 | 1 |
| Phase II | 126 | 1 |
| Phase III | 127 | 1 |
| Cervical Cancer Pipeline - Pre-Clinical | 128 | 1 |
| Cervical Cancer Pipeline - Phase I | 128 | 1 |
| Cervical Cancer Pipeline - Phase II | 129 | 1 |
| Cervical Cancer Pipeline - Phase III | 129 | 1 |
| Head and Neck Cancer | 130 | 1 |
| Head and Neck Cancer Pipeline - Introduction | 130 | 1 |
| Head and Neck Cancer Pipeline - Analysis by Therapeutic Class | 131 | 1 |
| Pre-Clinical | 131 | 1 |
| Discovery | 131 | 1 |
| Phase I | 132 | 1 |
| Phase II | 133 | 1 |
| Phase III | 134 | 1 |
| Head and Neck Cancer Pipeline - Pre-Clinical | 135 | 1 |
| Head and Neck Cancer Pipeline - Discovery | 135 | 1 |
| Head and Neck Cancer Pipeline - Phase I | 136 | 1 |
| Head and Neck Cancer Pipeline - Phase II | 137 | 2 |
| Head and Neck Cancer Pipeline - Phase III | 139 | 1 |
| Novel Therapies In Oncology - Promising Molecules | 140 | 14 |
| T-DM1 | 140 | 1 |
| Introduction | 140 | 1 |
| Mechanism of Action | 140 | 1 |
| Revenues | 140 | 1 |
| Afinitor (everolimus) | 141 | 1 |
| Introduction | 141 | 1 |
| Mechanism of Action | 141 | 1 |
| Revenues | 142 | 1 |
| Iniparib (E75) | 143 | 1 |
| Introduction | 143 | 1 |
| Mechanism of Action | 143 | 1 |
| Revenues | 144 | 1 |
| Afatinib | 145 | 1 |
| Introduction | 145 | 1 |
| Mechanism of Action | 145 | 1 |
| Revenues | 145 | 1 |
| Avastin | 146 | 1 |
| Introduction | 146 | 1 |
| Mechanism of Action | 146 | 1 |
| Revenues | 146 | 1 |
| Farletuzumab | 147 | 1 |
| Introduction | 147 | 1 |
| Mechanism of Action | 147 | 1 |
| Revenues | 148 | 1 |
| V503 | 149 | 1 |
| Introduction | 149 | 1 |
| Mechanism of Action | 149 | 1 |
| Revenues | 149 | 1 |
| Tykerb | 150 | 1 |
| Introduction | 150 | 1 |
| Mechanism of Action | 150 | 1 |
| Revenues | 151 | 1 |
| TheraCIM | 152 | 1 |
| Introduction | 152 | 1 |
| Mechanism of Action | 152 | 1 |
| Revenues | 153 | 1 |
| Novel Therapies In Oncology - Strategic Consolidations | 154 | 14 |
| M&A Landscape | 154 | 2 |
| M&A Deals by Year | 156 | 1 |
| M&A Deals by Geography | 157 | 1 |
| M&A Deals by Value | 158 | 1 |
| M&A Deals by Deal Type | 159 | 1 |
| R&D Licensing Agreements | 160 | 1 |
| Deals by Year | 161 | 1 |
| Deals by Geography | 162 | 1 |
| Deals by Value | 163 | 1 |
| Co-Development Agreements | 164 | 1 |
| Deals by Year | 165 | 1 |
| Deals by Geography | 166 | 1 |
| Deals by Value | 167 | 1 |
| Novel Therapies In Oncology - Appendix | 168 | 5 |
| Market Definitions | 168 | 1 |
| Abbreviations | 168 | 1 |
| Sources | 169 | 1 |